Role of medical rescue therapy in the management of acute severe ulcerative colitis: The surgical perspective

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 4, 2009, Pages 325-327

  Koltun, Walter A ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE;

ACUTE DISEASE; CANCER RISK; COLON RESECTION; COLORECTAL CANCER; CROHN DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DISEASE SURVEILLANCE; EDITORIAL; HISTOPLASMOSIS; HUMAN; ILEOSTOMY; IMMUNOSUPPRESSIVE TREATMENT; JEJUNOILEOSTOMY; LONG TERM CARE; LYMPHOMA; MALIGNANT TRANSFORMATION; MORTALITY; PNEUMOCYSTOSIS; QUALITY OF LIFE; RISK FACTOR; SURVIVAL; TUBERCULOSIS; ULCERATIVE COLITIS;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; COLONIC POUCHES; CYCLOSPORINE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DRUG RESISTANCE; GASTROINTESTINAL AGENTS; HUMANS; PATIENT SELECTION; PROCTOCOLECTOMY, RESTORATIVE; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 70049108329     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.34     Document Type: Editorial

References (10)

1. Doherty GA, Cheifetz AS. Management of acute severe ulcerative colitis. Expert Rev. Gastroenterol. Hepatol. 3(4), 395-405 (2009).
2. Mackey AC, Green L, Liang LC et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 44(2), 265-267 (2007).
3. Lichtenstein GR, Cohen RD, Feagan BG et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 4, 621-630 (2006).
4. Siegel CA, Marden SM, Persing SM et al. Risk of lymphoma associated with anti-TNF agents for the treatment of Crohn's disease: a meta-analysis. Gastroenterology 134(4 Suppl. 1), A144 (2008).
5. Zeddy JG, Loftus EV. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol. Clin. N. Am. 35, 837-855 (2006).
6. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462-2476 (2005).
7. Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134(4), 929-936 (2008).
8. Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflam. Bowel Dis. 5(1), 1-10 (1999).
9. Lichtenstein GR, Cohen R, Yamashita B, Diamond RH. Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. J. Clin. Gastroenterol. 40(8), 669-677 (2006).
10. Roberts SE, Williams JG, Yeates D et al. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. BMJ 335(7628), 1033 (2007).